AzTrials
AzTrials

Atrial FibrillationNCT04850508

Validation of the Advisor HD Grid Mapping Catheter in Atrial Fibrillation Ablation

An observational study of Atrial Fibrillation, run by University of Calgary at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The primary study concept is to evaluate the superiority of the HD Grid high-density mapping catheter over the current standard 20-pole circular mapping catheter in pulmonary vein isolation (PVI) in atrial fibrillation. Read more about this study

Who is it for?
Ages 18 to 85 years
Conditions the study is for
Atrial Fibrillation
What is being tested?
Mapping and ablation with the Advisor HD Grid catheter
Type of treatment
Medical device
How many people
20 participants
Where
1 siteCanada
Study dates
27 Sep 2021to 1 Nov 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Subjects with drug refractory, symptomatic atrial fibrillation scheduled for first PVI ablation.

Who may be able to join

  • Patients with symptomatic paroxysmal or persistent atrial Fibrillation.1
  • Patients referred for a clinically indicated catheter ablation with a plan for PVI only.
  • 18-85 year of age at time of consent.
  • Able and willing to comply with all protocol requirements.
  • Signed patient Informed Consent (ICF).

Who cannot join

  • History of prior left-sided catheter or surgical ablation for AF or atypical atrial flutter, including MAZE or mini MAZE. Prior ablation for typical atrial flutter or left-sided ablation for WPW, AV-node reentry tachycardia or right-sided focal ectopic atrial tachycardia may be included.
  • Planned for left atrial ablation beyond PVI.
  • Uncontrolled heart Failure or NYHA Class III or IV heart failure.
  • Left ventricular ejection fraction < 35 %
  • Left atrial size > 55 mm diameter on echocardiogram.
  • Severe Pulmonary Hypertension
Show all 15Show fewer
  • Reversible causes of AF (electrolyte imbalance, thyroid disease…)
  • Poor candidate for general anesthesia or deep sedation
  • Anticipated survival < 1 year
  • MI or CABG within 3 months, severe valvular disease
  • Any documented thromboembolic event within 6 months.
  • Contraindication to systemic oral anticoagulation therapy.
  • Significant congenital anomaly or medical condition that may affect the integrity of study data.
  • Women who are pregnant or breastfeeding.
  • Active enrollment in another investigational study involving a drug or device.

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • University of Calgary

    Calgary, Alberta, T2N 4Z6

Other trials in Canada

About this study

The primary study concept is to evaluate the superiority of the HD Grid high-density mapping catheter over the current standard 20-pole circular mapping catheter in pulmonary vein isolation (PVI) in atrial fibrillation. A minimum of 20 evaluable subjects with symptomatic atrial fibrillation scheduled for a clinically indicated first PVI ablation will be included.

Read the detailed description

Background and Rationale:

The main target in atrial fibrillation ablation is the isolation of the pulmonary veins (PVI). This is performed by point-by-point ablation with radiofrequency energy creating 2 circles, one around the left superior and inferior pulmonary vein and one around the right superior and inferior pulmonary vein. The current standard of mapping the pulmonary vein ostia during PVI ablation is a 20-pole circumferential catheter (CMC-20) which collects anatomical and electrical information by moving it in the left atrium and making contact with the atrial wall. Isolation of pulmonary veins is confirmed by other methods such as bidirectional block across the ablation lesions.

New technological developments have resulted in high-density mapping, such as the Advisor HD Grid mapping catheter by Abbott. This catheter has a total of 16 electrodes configured in a 4 by 4 matrix. With each electrical wavefront being decomposed to 2 orthogonal vectors, every direction of a local wavefront should be detected by these configurations and thus overcoming the bipolar blindness.

Research Question and Objectives:

The primary objective of this study is to demonstrate the superiority of the HD Grid catheter when compared to the CMC-20 catheter in atrial fibrillation ablation.

The primary endpoint is the mean number of gaps identified per patient, and their location identified by the HD Grid catheter after standard PVI procedure with the CMC-20 catheter.

Secondary endpoints are:

  • A per vein analysis will be performed for the presence of gaps and for the mean number of gaps.
  • A per pair of veins (left and right separately) analysis will be performed for the presence of gaps and for the mean number of gaps.
  • Left atrial mapping time for both the CMC-20 and the HD Grid catheter
  • Discrepancies in the prevalence of low voltage areas defined as a voltage <0.50 mV between the CMC-20 and HD Grid catheter in sinus rhythm.

Design:

Prospective, single arm, single center, superiority study with comparison of standard 20-pole circular mapping catheter and the new HD Grid multipolar catheter.

A minimum of 20 evaluable subjects with drug refractory, symptomatic atrial fibrillation scheduled for first PVI ablation will be enrolled over a period of 12 months.

Data collection:

Demographic, clinical and AF-related information will be collected prior to the procedure. Procedure related information will be collected directly after the procedure. All data will be collected in RedCap.

Procedure:

First, a standard PVI procedure is performed. After completion of the ablation lesions, isolation of the pulmonary veins will be confirmed using the standard CMC-20 catheter. If isolation is confirmed, the CMC-20 catheter will be exchanged for the HD Grid catheter. Using the HD Grid catheter, a new map of the left atrium will be made using the high-density settings. Together with the left atrium, the pulmonary veins will be mapped again in search of electro-anatomical gaps. Gaps are defined as a local area from the ablation line reaching inwards the pulmonary vein which still shows activation or fractionated potentials in line with atrial activation whilst pacing remote in the left atrium. The prevalence and location of these gaps will be collected using the map. If gaps have been found, HD Grid guided additional ablation must be performed to achieve isolation in that vein.

Being tested
Mapping and ablation with the Advisor HD Grid catheter
Keywords
Ablation
Medical subject headings
Atrial Fibrillation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Mapping and ablation with the Advisor HD Grid catheterDevice

    After confirmation of isolation of the first pair of veins, the CMC-20 catheter will be exchanged for the HD Grid catheter. Using the HD Grid catheter, a new map of the left atrium will be made using the high-density settings. Together with the left atrium, the pulmonary veins will be mapped again in search of electro-anatomical gaps. Gaps are defined as a local area from the ablation line reaching inwards the pulmonary vein which still shows activation or fractionated potentials in line with atrial activation whilst pacing remote in the left atrium. The After mapping the first ablation side, the CMC-20 will be reinserted to repeat the protocol for the remaining pair of veins 30 minutes after ablation ended for that side.

    If gaps have been found, HD Grid guided additional ablation must be performed to achieve isolation in that vein until isolation is reconfirmed.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of gaps

    The primary endpoint is the mean number of gaps identified per patient identified by the HD Grid catheter after standard PVI procedure with the CMC-20 catheter.

    Measured: During the ablation procedure.

  2. Location of gaps

    The co-primary endpoint is the location of the gaps identified per patient by the HD Grid catheter after standard PVI procedure with the CMC-20 catheter.

    Measured: During the ablation procedure.

Secondary outcomes (6)
  1. Per vein analysis for the presence of any gap.

    A per vein analysis will be performed for the presence of any gap as a binary outcome.

    Measured: During the ablation procedure.

  2. Per vein analysis for the mean number of gaps.

    A per vein analysis will be performed for the mean number of gaps.

    Measured: During the ablation procedure.

  3. Per pair of veins analysis for the presence of any gap.

    A per pair of veins (left and right separately) analysis will be performed for the presence of any gap as a binary outcome.

    Measured: During the ablation procedure.

  4. Per pair of veins analysis for the mean number of gaps.

    A per pair of veins (left and right separately) analysis will be performed for the mean number of gaps.

    Measured: During the ablation procedure.

  5. Mapping time

    Left atrial mapping time for both the CMC-20 and the HD Grid catheter

    Measured: During the ablation procedure.

  6. Discrepancies

    Discrepancies in the prevalence of low voltage areas defined as a voltage <0.50 mV between the CMC-20 and HD Grid catheter in sinus rhythm.

    Measured: During the ablation procedure.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Apr 2021
  2. Study start27 Sep 2021
  3. Primary completion1 Nov 2022
  4. Study completion1 Nov 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04850508
Sponsor's protocol ID
REB20-2140
Status last verified
Nov 2022
First submitted
13 Apr 2021
Last updated
15 Nov 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Given the small number of patients in the study individual treatments and outcomes maybe looked at.

Publications

  • Porterfield C, J Gora P, Wystrach A, Rossi P, Rillo M, A Sebag F, Giuggia M, Mantica M, Dorszewski A, Eldadah Z, Volpicelli M, Bottoni N, Jons C, T Hollis Z, Dekker L, Mathew S, Schmitt J, Nilsson K. Confirmation of Pulmonary Vein Isolation with High-Density Mapping: Comparison to Traditional Workflows. J Atr Fibrillation. 2020 Apr 30;12(6):2361. doi: 10.4022/jafib.2361. eCollection 2020 Apr-May.

    PubMed 33024494
  • Vandenberk B, Quinn FR, Barmby J, Wilton SB, Kuriachan V. High-density mapping improves detection of conduction gaps after pulmonary vein isolation ablation with a circular mapping catheter. J Interv Card Electrophysiol. 2023 Sep;66(6):1401-1410. doi: 10.1007/s10840-022-01434-3. Epub 2022 Dec 3.

    PubMed 36462064

Questions about this trial

What is this clinical trial studying?

An observational study of Atrial Fibrillation, run by University of Calgary at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of gaps (time frame: During the ablation procedure.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04850508, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Nov 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in